Anticoagulation control in the peri-hospitalization period

Journal of General Internal Medicine

Volumn 22, Issue 6, 2007, Pages 727-735

  Van Walraven, Carl ^a,b   Forster, Alan J ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Anticoagulation; Hospitalization; Time series analysis

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DATA BASE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THROMBOSIS; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COHORT STUDIES; DATABASES; FEMALE; HOSPITALIZATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; RETROSPECTIVE STUDIES;

EID: 34248573619     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-006-0064-5     Document Type: Article

References (35)

1. van Walraven C, Austin PC, Oake N, Wells PS, Mamdani M, Forster AJ. The influence of hospitalization on oral anticoagulation control: a population-based study. Thromb Res. 2006. (In press)
2. Tangelder MJD, Algra A, Lawson JA, Hennekes S, Eikelboom BC. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. J Vasc Surg. 2001;33(3):522-27.
3. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11-7.
4. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der MJ, Veeger NJGM et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513-19.
5. Palareti G, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost. 1997;78(6):1438-43.
6. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 2002;325(7372):1073-5.
7. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42(6):857-65.
8. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333(1):5-10.
9. Azar AJ, Cannegieter SC, Deckers JW, Briet E, van Bergen PF, Jonker JJ et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol. 1996;27(6):1349-55.
10. Casais P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol. 2000;63(4):192-6.
11. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348 (9025):423-8.
12. van Walraven C, Jennings A, Oakes N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest. 2006;129:1155-66.
13. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart (British Cardiac Society). 2005;91(4):472-7.
14. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279(9):657-62.
15. van Walraven C, Raymond M, Network for the Eastern Ontario Medical Laboratories. A population-based study of repeat laboratory testing. Clin Chem. 2003;49:1997-2005.
16. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9.
17. Hutten BA, Prins MH, Redekop WK, Tijssen JG, Heisterkamp SH, Buller HR. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost. 1999;82(4):1260-3.
18. Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006;118:253-62.
19. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001;10(6):785-92.
20. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):8S-21S.
21. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000;160(11):1612-7.
22. Austin PC, Hux JE. A brief note on overlapping confidence intervals. J Vasc Surg. 2002;36(1):194-5.
23. van Walraven C, Goel V, Chan B. Effect of population-based interventions on laboratory utilization: a time-series analysis. JAMA. 1998;280(23):2028-33.
24. van Walraven C, Goel V. The effect of a hepatitis serology testing algorithm on laboratory utilization. J Eval Clin Pract. 2002;8:327-32.
25. Bunting PS, van Walraven C. Effect of a controlled feedback intervention on laboratory test ordering by community physicians. Clin Chem. 2004;50(2):321-6.
26. Yaffee R. Introduction to Time Series Analysis and Forcasting with Applications of SAS and SPSS. Boston: Academic Press Inc; 2000.
27. Brocklebank JC, Dickey DA. SAS for Forecasting Time Series. Second ed. Cary: SAS Institute; 2003.
28. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348 (9025):423-8.
29. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000;133(9):687-95.
30. Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J. 1982;103 (3):445-46.
31. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med. 1984;144(10):1966-8.
32. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118(7):511-20.
33. Wilson SJ-A, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Can Med Assoc J. 2003;169(4):293-8.
34. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-6.
35. Tu JV, Naylor CD, Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996. CMAJ (Can Med Assoc J). 1999;161(10):1257-61.